We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
The BIB Wine Company is, according to the Independent, the first-ever luxury Bag-in-Box wine company. The BIB Wine Company has received excellent reviews from critics and has been given a 4.6 stars rating on reviews.co.uk. The company's Head of Wine has previously headed up wine at Waitrose & Laithwaites. It has sold an equivalent of more than 11,400 bottles in the first year of production. In August 2019, the company's YoY growth hit 200%. The BIB Wine Company has also been nominated for two category awards in the People's Choice Wine Awards. With the proceeds, the company will increase the digital spend to local workers and residents.
days to go: Expired investment: £189,695
We created FlyFit with the aim to change the way people travel. Air travel can be stressful, lonely, and unhealthy. On top of this, with average layovers of 2+ hours, flight delays, and hours waiting in security, there is too much unproductive time in airports with limited healthy options to choose from.
days to go: Expired investment: £500,060
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.   
days to go: Expired investment: £30,564
A protein energy brand that offers its products in round balls as an easy-to-eat pre and post workout snack. Boostball's multi-award winning products are made from raw ingredients that have been cold-pressed and only contain natural sugars from fruits and plants. Boostball sells almost 50,000 units per month across 13 countries and have their own production facility, which creates products for other companies too. Boostball has partnered with Virgin Atlantic and Wimbledon to market their range and their customers also include Google, WHSmith and Graze. Funds are being raised to launch their next product range, Boostbutter, which is nut butter in squeezable pouches of various sizes. The business is also seeking to grow their market share by entering other territories such as the USA.
days to go: Expired investment: £251,300
Hop Stuff are a rapidly growing London brewery which was founded in late 2013, they have grown over 400% in just 3 years. They are now looking to expand both their brewery and bars, becoming one of London’s biggest independent brewers.
days to go: Expired investment: £744,850
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph